Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

NCT02464670 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT02464670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02464670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
May 24, 2018
Enrollment
240 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ebola vaccine